Plus Therapeutics (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our lead drug candidate, Rhenium-186 Nanoliposome, is being evaluated in the NIH-supported multi-center ReSPECT clinical trials for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.